Generic Medicine Info
Indications and Dosage
Minor infections of the mouth and throat
Adult: As loz containing 250 mcg dequalinium: Suck 1 loz 2-3 hourly. Max: 8 loz daily.
Child: >10 years Same as adult dose.

Bacterial vaginosis
Adult: Insert 10 mg vaginal tab once daily for 6 days.
Incompatible with soaps, anionic surfactants, phenol, chlorocresol.
Children <6 year (oral). Ulceration of the vaginal epithelium and portio, young girls who have not yet had first menstruation (vaginal).
Special Precautions
Children Pregnancy and lactation.
Adverse Reactions
Gastrointestinal disorders: Glossodynia (oral).
Reproductive system and breast disorders: Vaginal discharge, vulvovaginal pruritus, vulvovaginal burning sensation.
Patient Counseling Information
Avoid use of vaginal tab within 12 hours before birth.
Symptoms: Gastrointestinal discomfort (oral); vaginal ulceration (vaginal). Management: Symptomatic and supportive treatment (oral); vaginal lavage (vaginal).
Description: Dequalinium is a bisquanternary quinolinium anti-infective agent against gram-positive and gram-negative bacteria, fungi, protozoa and yeast. It increases bacterial cell permeability and reduces enzymatic activity, thus causing cell death.
Onset: Within 30-60 minutes.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Dequalinium, CID=2993, (accessed on Jan. 20, 2020) Copy

Store below 25°C.
MIMS Class
Preparations for Oral Ulceration & Inflammation / Preparations for Vaginal Conditions
Buckingham R (ed). Dequalinium Chloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. . Accessed 03/08/2018.

Dequadin (Reckitt Benckiser Healthcare UK Limited). MHRA. . Accessed 03/08/2018.

Fluomizin 10 mg Vaginal Tablets (Kora Corporation Ltd). MHRA. Accessed 03/08/2018.

Joint Formulary Committe. Dequalinium Chloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 03/08/2018.

Disclaimer: This information is independently developed by MIMS based on Dequalinium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Delin
  • Dexxon
  • Nofrozic
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in